Financings in Brief: IsoTis BV
This article was originally published in The Gray Sheet
IsoTis BV: Private financing round led by existing shareholder Atlas Venture and including new investors GIMV and 3i raises $2 mil. The privately held developer of hybrid technology for application in hard and soft tissue replacement notes the financing "will enable us to accelerate the development of our biomimetic and tissue engineering bone and skin replacement products." Bilthoven, The Netherlands-based IsoTis recently changed its name from Matrix Medical; the new name is "analogous" to the firm's replacement tissue technologies and means "equal to tissue," IsoTis explains...
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.